Canadian Meds |
Policy | Legal
Terms | Meds Index
Drug class - proton pump inhibitors
Main indication - GERD, helicobacter pylori diseases
Administration type - oral intake
Manufacturer - EISAI (Johnson & Johnson)
Pregnancy category - no proven risk in humans
FDA records - starting from 1999
The active ingredient of Pariet is sodium rabeprazole. After absorption of Pariet in gastric cavity the enzyme providing secretion from cells in body cavity of hydrogen protons is blocked, disrupting the formation of hydrochloric acid. Pariet onset of action is observed after about an hour after administration, protecting the stomach up to 48 hours. The maximum effect is observed in patients after 4 hours after drug administration. After the abolition of secretion it is restored to its previous level for 2-3 days.
The above described action is observed when rabeprazole sodium is taken to combat Helicobacter pylori - the bacterium that causes inflammation of the mucous layer of the stomach wall. Pariet, according to the reviews by clinical physicians, does not cause changes in metabolism, does not violate the cardiovascular, nervous, excretory systems of the body, does not cause changes in the respiratory system, and is largely considered to be a well-tolerated drug.
Release form and composition of the drug
Pariet is available in tablets containing 10 and 20 mg of the active ingredient (rabeprazole sodium). The tablets have different colors depending on the dosage - 10 mg pink and 20 mg - yellow ones.
The application of Pariet according to the insert is shown in the following cases:
• the acute form of gastric ulcer;
• duodenal ulcer, including the acute stage;
• hypersecretion of hydrochloric acid (Zollinger-Ellison syndrome);
• helicobacter pylori infection.
Instructions for use
In case of peptic ulcer the preparation is used as follows: 20 mg is appointed for a single intake daily. According to the instructions, it is desirable to take Pariet in the morning before a meal; although it is not strictly necessary in terms of the impact of the drug, however, the discipline of the patient allows to adhere to treatment regimens more accurately. The tablet is swallowed whole without chewing, with plenty of water. The treatment of peptic ulcer disease typically ranges from 4 to 6 weeks. In most cases, after 4 weeks of Pariet application it is possible to achieve remission. If it does not, an extra treatment course for another 4 weeks can be initiated.
In gastroesophageal reflux disease 1 tablet (20 mg of rabeprazole sodium) in the morning before eating is appointed. The treatment course duration ranges from 4 to 8 weeks. After elimination of the acute symptoms of the disease the dose is reduced to 10 mg per day, and this dose as a maintenance therapy is recommended for continuous use.
In treatment of Helicobacter pylori Pariet therapy is designed for 7 days, during which the drug is administered in a dosage of 2 tablets of 20 mg 2 times a day (in the morning and evening before the meal). To improve the efficiency of treatment in this case Pariet is used in combination with other antibacterial agents.
The contraindications are the following:
• hypersensitivity to the components of the drug;
• pregnancy and lactation women (there is no confirmed, comprehensive information on the preparation’s safety in this case);
• in children under 18 years old using the preparation is not recommended;
• malignant disease of the gastrointestinal tract.
In accordance with the instructions, in combination with other drugs Pariet can be taken only after a professional consultation, since the interactions with other drugs can cause undesirable adverse reactions.
© 2003-2017 Rx Meds Canada . All Rights Reserved